- Home
- GUTS vs ASRT Comparison
GUTS vs ASRT Comparison
Compare GUTS & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- ASRT
- Stock Information
- Founded
- GUTS 2010
- ASRT 1995
- Country
- GUTS United States
- ASRT United States
- Employees
- GUTS N/A
- ASRT N/A
- Industry
- GUTS
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- ASRT Health Care
- Exchange
- GUTS NYSE
- ASRT Nasdaq
- Market Cap
- GUTS 110.1M
- ASRT 91.3M
- IPO Year
- GUTS 2024
- ASRT 1997
- Fundamental
- Price
- GUTS $2.03
- ASRT $0.90
- Analyst Decision
- GUTS Buy
- ASRT Strong Buy
- Analyst Count
- GUTS 2
- ASRT 4
- Target Price
- GUTS $18.00
- ASRT $3.19
- AVG Volume (30 Days)
- GUTS 275.0K
- ASRT 908.1K
- Earning Date
- GUTS 02-02-2025
- ASRT 11-11-2024
- Dividend Yield
- GUTS N/A
- ASRT N/A
- EPS Growth
- GUTS N/A
- ASRT N/A
- EPS
- GUTS N/A
- ASRT N/A
- Revenue
- GUTS $97,000.00
- ASRT $125,763,000.00
- Revenue This Year
- GUTS N/A
- ASRT N/A
- Revenue Next Year
- GUTS N/A
- ASRT $1.84
- P/E Ratio
- GUTS N/A
- ASRT N/A
- Revenue Growth
- GUTS N/A
- ASRT N/A
- 52 Week Low
- GUTS $1.74
- ASRT $0.73
- 52 Week High
- GUTS $14.50
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- GUTS 43.94
- ASRT 43.20
- Support Level
- GUTS $1.99
- ASRT $0.90
- Resistance Level
- GUTS $2.58
- ASRT $1.04
- Average True Range (ATR)
- GUTS 0.19
- ASRT 0.06
- MACD
- GUTS -0.02
- ASRT -0.00
- Stochastic Oscillator
- GUTS 13.01
- ASRT 14.84
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.